PTEN decreases in Vivo vascularization of experimental gliomas in spite of proangiogenic stimuli

Cancer Research

Volumn 63, Issue 9, 2003, Pages 2300-2305

  Abe, Tatsuya ^a   Terada, Kinya ^a   Wakimoto, Hiroaki ^a   Inoue, Ryo ^a   Tyminski, Edyta ^a   Bookstein, Robert ^b   Basilion, James P ^a   Chiocca, E Antonio ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c MA GenHosp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA TRANSFER; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; TUMOR VASCULARIZATION; XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; FEMALE; GENE THERAPY; GENETIC VECTORS; GLIOMA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; RATS; RATS, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037699025     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., Frye, C., Hu, R., Swedlund, B., Teng, D. H., and Tavtigian, S. V. Identification of a candidate tumour suppressor gene, MMAC 1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet., 15: 356-362, 1997.
2. Marsh, D. J., Dahia, P. L., Zheng, Z., Liaw, D., Parsons, R., Gorlin, R. J., and Eng, C. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat. Genet., 16: 333-334, 1997.
3. Maehama, T., and Dixon, J. E. The tumor suppressor, PTEN/MMAC, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J. Biol. Chem., 273: 13375-13378, 1998.
4. Fruman, D. A., Meyers, R. E., and Cantley, L. C. Phosphoinositide kinases. Annu. Rev. Biochem., 67: 481-507, 1998.
5. Cheney, I. W., Johnson, D. E., Vaillancourt, M. T., Avanzini, J., Morimoto, A., Demers, G. W., Wills, K. N., Shabram, P. W., Bolen, J. B., Tavtigian, S. V., and Bookstein, R. Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMACI/PTEN gene transfer. Cancer Res., 58: 2331-2334, 1998.
6. Aoki, M., Batista, O., Bellacosa, A., Tsichlis, P., and Vogt, P. K. The akt kinase: molecular determinants of oncogenicity. Proc. Natl. Acad. Sci. USA, 95: 14950-14955, 1998.
7. Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M. E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 91: 231-241, 1997.
8. Holland, E. C., Celestino, J., Dai, C., Schaefer, L., Sawaya, R. E., and Fuller, G. N. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat. Genet., 25: 55-57, 2000.
9. Khwaja, A., Rodriguez-Viciana, P., Wennstrom, S., Warne, P. H., and Downward, J. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J., 16: 2783-2793, 1997.
10. Pap, M., and Cooper, G. M. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J. Biol. Chem., 273: 19929-19932, 1998.
11. Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., and Greenberg, M. E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell, 96: 857-868, 1999.
12. Kops, G. J., and Burgering, B. M. Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling. J. Mol. Med., 77: 656-665, 1999.
13. Davies, M. A., Lu, Y., Sano, T., Fang, X., Tang, P., LaPushin, R., Koul, D., Bookstein, R., Stokoe, D., Yung, W. K., Mills, G. B., and Steck, P. A. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res., 58: 5285-5290, 1998.
14. Haas-Kogan, D., Shalev, N., Wong, M., Mills, G., Yount, G., and Stokoe, D. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr. Biol., 8: 1195-1198, 1998.
15. Li, J., Simpson, L., Takahashi, M., Miliaresis, C., Myers, M. P., Tonks, N., and Parsons, R. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res., 58: 5667-5672, 1998.
16. Diehl, J. A., Cheng, M., Roussel, M. F., and Sherr, C. J. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev., 12: 3499-3511, 1998.
17. Mazure, N. M., Chen, E. Y., Laderoute, K. R., and Giaccia, A. J. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood, 90: 3322-3331, 1997.
18. Wen, S., Stolarov, J., Myers, M. P., Su, J. D., Wigler, M. H., Tonks, N. K., and Durden, D. L. PTEN controls tumor-induced angiogenesis. Proc. Natl. Acad. Sci. USA, 98: 4622-4627, 2001.
19. Wesseling, P., Ruiter, D. J., and Burger, P. C. Angiogenesis in brain tumors; pathobiological and clinical aspects. J. Neurooncol., 32: 253-265, 1997.
20. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.
21. Schober, R., Bilzer, T., Waha, A., Reifenberger, G., Wechsler, W., von Deimling, A., Wiestler, O. D., Westphal, M., Kemshead, J. T., Vega, F., et al. The epidermal growth factor receptor in glioblastoma: genomic amplification, protein expression, and patient survival data in a therapeutic trial. Clin. Neuropathol., 14: 169-174, 1995.
22. Maity, A., Pore, N., Lee, J., Solomon, D., and O'Rourke, D. M. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res., 60: 5879-5886, 2000.
23. Viloria-Petit, A., Crombet, T., Jothy, S., Hicklin, D., Bohlen, P., Schlaeppi, J. M., Rak, J., and Kerbel, R. S. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res., 61: 5090-5101, 2001.
24. Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., Hicklin, D. J., Radinsky, R., and Dinney, C. P. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res., 5: 257-265, 1999.
25. Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Fontanini, G., Cuccato, S., De Placido, S., Bianco, A. R., and Tortora, G. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res., 7: 1459-1465, 2001.
26. Ravindranath, N., Wion, D., Brachet, P., and Djakiew, D. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J. Androl., 22: 432-443, 2001.
27. Kleihues, P., and Ohgaki, H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncol., 1: 44-51, 1999.
28. Bouvet, M., Ellis, L. M., Nishizaki, M., Fujiwara, T., Liu, W., Bucana, C. D., Fang, B., Lee, J. J., and Roth, J. A. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res., 58: 2288-2292, 1998.
29. Dameron, K. M., Volpert, O. V., Tainsky, M. A., and Bouck, N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (Wash. DC), 265: 1582-1584, 1994.
30. Tenan, M., Fulci, G., Albertoni, M., Diserens, A. C., Hamou, M. F., El Atifi-Borel, M., Feige, J. J., Pepper, M. S., and Van Meir, E. G. Thrombospondinis down-regulated by anoxia and suppresses tumorigenicity of human glioblastoma cells. J. Exp. Med., 191: 1789-1798, 2000.
31. Van Meir, E. G., Polverini, P. J., Chazin, V. R., Su Huang, H. J., de Tribolet, N., and Cavenee, W. K. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat. Genet., 8: 171-176, 1994.
32. Nishimori, H., Shiratsuchi, T., Urano, T., Kimura, Y., Kiyono, K., Tatsumi, K., Yoshida, S., Ono, M., Kuwano, M., Nakamura, Y., and Tokino, T. A novel brain-specific p53-target gene, BAII, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene, 15: 2145-2150, 1997.
33. Blagosklonny, M. V., An, W. G., Romanova, L. Y., Trepel, J., Fojo, T., and Neckers, L. p53 inhibits hypoxia-inducible factor-stimulated transcription. J. Biol. Chem., 273: 11995-11998, 1998.
34. Zhang, L., Yu, D., Hu, M., Xiong, S., Lang, A., Ellis, L. M., and Pollock, R. E. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res., 60: 3655-3661, 2000.
35. Nagane, M., Coufal, F., Lin, H., Bogler, O., Cavenee, W. K., and Huang, H. J. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res., 56: 5079-5086, 1996.
36. Huyghe, B. G., Liu, X., Sutjipto, S., Sugarman, B. J., Horn, M. T., Shepard, H. M., Scandella, C. J., and Shabram, P. Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum. Gene Ther., 6: 1403-1416, 1995.
37. Bell, M. A., and Scarrow, W. G. Staining for microvascular alkaline phosphatase in thick celloidin sections of nervous tissue: morphometric and pathological applications. Microvasc. Res., 27: 189-203, 1984.
38. Abe, T., Okamura, K., Ono, M., Kohno, K., Mori, T., Hori, S., and Kuwano, M. Induction of vascular endothelial tubular morphogenesis by human glioma cells. A model system for tumor angiogenesis. J. Clin. Investig., 92: 54-61, 1993.
39. Mishima, K., Johns, T. G., Luwor, R. B., Scott, A. M., Stockert, E., Jungbluth, A. A., Ji, X. D., Suvarna, P., Voland, J. R., Old, L. J., Huang, H. J., and Cavenee, W. K. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res., 61: 5349-5354, 2001.
40. Ishii, N., Maier, D., Merlo, A., Tada, M., Sawamura, Y., Diserens, A. C., and Van Meir, E. G. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol., 9: 469-479, 1999.
41. Yuan, A., Yu, C. J., Luh, K. T., Kuo, S. H., Lee, Y. C., and Yang, P. C. Aberrant p53 Expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small cell lung cancer. J. Clin. Oncol., 20: 900-910, 2002.
42. Tai, Y. T., Podar, K., Gupta, D., Lin, B., Young, G., Akiyama, M., and Anderson, K. C. CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells. Blood, 99: 1419-1427, 2002.
43. Fontanini, G., Vignati, S., Lucchi, M., Mussi, A., Calcinai, A., Boldrini, L., Chine, S., Silvestri, V., Angeletti, C. A., Basolo, F., and Bevilacqua, G. Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. Br. J. Cancer, 75: 1295-1301, 1997.
44. Pal, S., Datta, K., and Mukhopadhyay, D. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res., 61: 6952-6957, 2001.
45. Linderholm, B. K., Lindahl, T., Holmberg, L., Klaar, S., Lennerstrand, J., Henriksson, R., and Bergh, J. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res., 61: 2256-2260, 2001.
46. Galy, B., Creancier, L., Zanibellato, C., Prats, A. C., and Prats, H. Tumour suppressor p53 inhibits human fibroblast growth factor 2 expression by a post-transcriptional mechanism. Oncogene, 20: 1669-1677, 2001.
47. Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., and Bedi, A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev., 14: 34-44, 2000.
48. Kieser, A., Weich, H. A., Brandner, G., Marme, D., and Kolch, W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene, 9: 963-969, 1994.
49. Ram, T. G., and Ethier, S. P. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. Cell Growth Differ., 7: 551-561, 1996.
50. Kwak, C., Jin, R. J., Lee, C., Park, M. S., and Lee, S. E. Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia. BJU Int., 89: 303-309, 2002.
51. Plate, K. H., Breier, G., Weich, H. A., Mennel, H. D., and Risau, W. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int. J. Cancer, 59: 520-529, 1994.
52. Strohmeyer, D., Rossing, C., Bauerfeind, A., Kaufmann, O., Schlechte, H., Bartsch, G., and Loening, S. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate, 45: 216-224, 2000.
53. Nozaki, M., Tada, M., Kobayashi, H., Zhang, C. L., Sawamura, Y., Abe, H., Ishii, N., and Van Meir, E. G. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. Neuro-oncol., 1: 124-137, 1999.
54. Thorsen, F., and Tysnes, B. B. Brain tumor cell invasion, anatomical and biological considerations. Anticancer Res., 17: 4121-4126, 1997.
55. Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., Gottschalk, A. R., Ryan, H. E., Johnson, R. S., Jefferson, A. B., Stokoe, D., and Giaccia, A. J. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev., 14: 391-396, 2000.
56. Yen, L., You, X. L., Al Moustafa, A. E., Batist, G., Hynes, N. E., Mader, S., Meloche, S., and Alaoui-Jamali, M. A. Heregulin selectively up-regulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene, 19: 3460-3469, 2000.